linezolid

Linezolid (PNU-100766), the first of the oxazolidinone class, is a synthetic antibiotic used for the therapy of infections resulted from multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcus. The drug takes effect as the inhibitor of the initiation of bacterial protein synthesis.

Demethyl linezolid is an impurity observed in linezolid, an antimicrobial compound. It exhibits effective antimicrobial properties against various human and veterinary pathogens.

(R)-Linezolid, an impurity of Linezolid, inhibits the initiation of bacterial protein synthesis.

Linezolid D3, a deuterium-labeled version of Linezolid, is a synthetic antibiotic designed to halt the initiation of bacterial protein synthesis.

PNU-100440 is a biologically active compound. It is an intermediate in the synthesis of linezolid dimers, an impurity of the antibacterial agent Linezolid.

(S)-N-Glycidylphthalimide (2-[(2S)-2-Oxiranylmethyl]-1H-isoindole-1,3(2H)-dione) is a phthalimide derivative used as an intermediate in the preparation of the antibiotic Linezolid.

YycG inhibitor 16 is a novel YycG inhibitor, inhibiting planktonic cells of E. faecalis, including the vancomycin- or linezolid-resistant strains.

Lytixar is a Synthetic Antimicrobial Peptide, it shows activity against Daptomycin-Nonsusceptible, Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Linezolid-Nonsusceptible Staphylococcus aureus. LTX-109 demonstrated a MIC range o

BDM88855 is a conformational inhibitor of the homologous AcrB protein. This compound enhances the antibacterial effects of a range of antibiotics (such as: benzylpenicillin, linezolid, neomycin) against wild-type Escherichia coli.

DA-7867 is a novel oxazolidinone. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested (≤0.25 μg/ml) and it was more potent than linezolid. DA-7867 was the most active drug with a MIC(90) of 0.125 μg/ml.

Suvratoxumab (MEDI4893) is a high-affinity, long-acting humanized IgG1κ anti-α-toxin monoclonal antibody. It effectively neutralizes α-toxin, a principal virulence factor of S. aureus, enhancing survival and diminishing lung injury in an immunocompromised mouse model of pneumonia. Additionally, Suvratoxumab augments the antibacterial efficacy of Vancomycin and Linezolid [1] [2] [3].

PNU 142300 is an inactive metabolite of the oxazolidinone antibiotic linezolid .

CAY10742 is an orally bioavailable oxadiazole antibiotic.1It is active against the Gram-positive bacteriaS. aureus,S. epidermidis,S. haemolyticus,B. cereus,B. licheniformis,E. faecalis, andE. faecium(MICs = 1-4 μg/ml), including laboratory strains and clinical isolates with varying degrees of resistance to methicillin, vancomycin, linezolid, and other antibiotics. CAY10742 (40 mg/kg) reduces the number of bacteria in mouse neutropenic thigh models of linezolid-sensitive or -resistant methicillin-resistantS. aureus(MRSA) infection. 1.Boudreau, M.A., Ding, D., Meisel, J.E., et al.Structure-activity relationship for the oxadiazole class of antibacterialsMed. Chem. Lett.11(3)322-326(2019)

BDM88855 hydrochloride acts as a conformational inhibitor of the homologous AcrB protein. It enhances the antimicrobial activity of a range of antibiotics (such as benzylpenicillin, linezolid, and neomycin) against wild-type Escherichia coli.

Tedizolid HCl is a reversible, novel oxazolidinone antibiotic (IC50: for MAO-A (monoamine oxidase-A), 8.7 uM; for MAO-B, 5.7 uM). It is the first oxazolidinone to be approved since linezolid in 2000. Tedizolid phosphate is the second commercially availabl

Radezolid (RX-1741) is a novel oxazolidinone antibiotic.

Delpazolid (LCB01-0371), also known as LCB01-0371, is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.